Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Cytek BioSciences Inc (NASDAQ: CTKB) was $5.80 for the day, down -2.03% from the previous closing price of $5.92. In other words, the price has decreased by $-2.03 from its previous closing price. On the day, 0.52 million shares were traded. CTKB stock price reached its highest trading level at $5.89 during the session, while it also had its lowest trading level at $5.695.
Ratios:
Our analysis of CTKB’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1204.37. For the most recent quarter (mrq), Quick Ratio is recorded 5.89 and its Current Ratio is at 6.97. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on December 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $9.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 09 ’24 when Yan Ming sold 1,900 shares for $7.00 per share. The transaction valued at 13,304 led to the insider holds 6,008,502 shares of the business.
Yan Ming sold 20,000 shares of CTKB for $134,200 on Mar 19 ’24. The CHIEF TECHNOLOGY OFFICER now owns 6,010,402 shares after completing the transaction at $6.71 per share. On Mar 18 ’24, another insider, Yan Ming, who serves as the CHIEF TECHNOLOGY OFFICER of the company, sold 20,000 shares for $6.77 each. As a result, the insider received 135,400 and left with 6,030,402 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 758779200 and an Enterprise Value of 510505600. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.93 while its Price-to-Book (P/B) ratio in mrq is 1.93. Its current Enterprise Value per Revenue stands at 2.645 whereas that against EBITDA is -25.152.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.39, which has changed by -0.39393938 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $12.31, while it has fallen to a 52-week low of $3.80. The 50-Day Moving Average of the stock is -20.05%, while the 200-Day Moving Average is calculated to be -20.69%.
Shares Statistics:
CTKB traded an average of 698.58K shares per day over the past three months and 795360 shares per day over the past ten days. A total of 130.71M shares are outstanding, with a floating share count of 118.77M. Insiders hold about 9.22% of the company’s shares, while institutions hold 60.17% stake in the company. Shares short for CTKB as of 1711584000 were 9948484 with a Short Ratio of 14.24, compared to 1709164800 on 7794283. Therefore, it implies a Short% of Shares Outstanding of 9948484 and a Short% of Float of 8.649999999999999.
Earnings Estimates
The current market rating for Cytek BioSciences Inc (CTKB) reflects the collective analysis of 6 analysts closely monitoring its performance.On average, analysts expect EPS of $-0.04 for the current quarter, with a high estimate of $-0.02 and a low estimate of $-0.07, while EPS last year was $-0.05. The consensus estimate for the next quarter is $-0.03, with high estimates of $-0.02 and low estimates of $-0.04.
Analysts are recommending an EPS of between $0 and $-0.1 for the fiscal current year, implying an average EPS of $-0.04. EPS for the following year is $0.1, with 6 analysts recommending between $0.21 and $-0.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $46.18M to a low estimate of $41.59M. As of the current estimate, Cytek BioSciences Inc’s year-ago sales were $37.09M, an estimated increase of 17.50% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $49.34M, an increase of 7.90% less than the figure of $17.50% in the same quarter last year. There is a high estimate of $50.9M for the next quarter, whereas the lowest estimate is $47.54M.
A total of 6 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $205.2M, resulting in an average revenue estimate of $207.89M. In the same quarter a year ago, actual revenue was $193.01M, up 7.70% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $247.08M in the next fiscal year. The high estimate is $266.8M and the low estimate is $224.85M. The average revenue growth estimate for next year is up 18.90% from the average revenue estimate for this year.
